falsefalse

Optimizing Bruton Kinase (BTK) Inhibitors in Relapsed/Refractory (R/R) Mantle Cell Lymphoma - Episode 7

Future Directions in the Treatment of Mantle Cell Lymphoma

,

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, close their discussion with a look at the future treatment landscape of mantle cell lymphoma.

Current Time 0:00
Duration 7:36
Loaded: 0%
Stream Type LIVE
Remaining Time 7:36
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Overview of Mantle Cell Lymphoma
EP. 2: Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma
EP. 3: Role of Maintenance Therapy in Newly Diagnosed Mantle Cell Lymphoma
EP. 4: Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma
EP. 5: Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma
EP. 6: Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma
Now Viewing
EP. 7: Future Directions in the Treatment of Mantle Cell Lymphoma

Related Content:

Optimizing Bruton Kinase (BTK) Inhibitors in Relapsed/Refractory (R/R) Mantle Cell LymphomaMantle Cell LymphomaInsights
FDA Approves Generic Ibrutinib Tablets for B-Cell Malignancies
European Commission Approves Ibrutinib in Treatment-Naive, Transplant-Eligible MCL
Beyond Single Biomarkers: How Emerging Data Might Transform Biomarker Testing
x